146 related articles for article (PubMed ID: 38041540)
1. Novel molecular insights into pyroptosis in triple-negative breast cancer prognosis and immunotherapy.
Yu B; Luo J; Yang Y; Zhen K; Shen B
J Gene Med; 2024 Jan; 26(1):e3645. PubMed ID: 38041540
[TBL] [Abstract][Full Text] [Related]
2. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
3. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
Zhang J; Zhang M; Tian Q; Yang J
Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
[TBL] [Abstract][Full Text] [Related]
4. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
[TBL] [Abstract][Full Text] [Related]
5. A pyroptosis-associated gene risk model for predicting the prognosis of triple-negative breast cancer.
Qiu P; Guo Q; Pan K; Chen J; Lin J
Front Oncol; 2022; 12():890242. PubMed ID: 36276158
[TBL] [Abstract][Full Text] [Related]
6. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247
[TBL] [Abstract][Full Text] [Related]
7. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
Yang X; Tang W; He Y; An H; Wang J
Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
[TBL] [Abstract][Full Text] [Related]
8. Genomic and Immunological Characterization of Pyroptosis in Lung Adenocarcinoma.
Song Y; Qu Z; Feng H; Xu L; Xiao Y; Zhao Z; Wu D; Sun C; Fan X; Zhou D
J Oncol; 2022; 2022():6905588. PubMed ID: 35938142
[TBL] [Abstract][Full Text] [Related]
9. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer.
Cao T; Huang M; Huang X; Tang T
PeerJ; 2024; 12():e16935. PubMed ID: 38435998
[TBL] [Abstract][Full Text] [Related]
10. Development of an ubiquitin-proteasome system signature for predicting prognosis and providing therapeutic guidance for patients with triple-negative breast cancer.
Chen X; Ren C; Zhou Z; Chen J; Fan X; Li X; Chen J; Zhu J
J Gene Med; 2024 Jan; 26(1):e3584. PubMed ID: 37605934
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Pyroptosis-Related Subtypes
Li C; Pan J; Jiang Y; Wu Y; Jin Z; Chen X
Front Genet; 2022; 13():788670. PubMed ID: 35386285
[TBL] [Abstract][Full Text] [Related]
12. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
Shen X; Zhong J; He J; Han J; Chen N
Front Immunol; 2022; 13():978092. PubMed ID: 36105819
[TBL] [Abstract][Full Text] [Related]
13. Immune landscape and risk prediction based on pyroptosis-related molecular subtypes in triple-negative breast cancer.
Luo L; Wei Q; Xu C; Dong M; Zhao W
Front Immunol; 2022; 13():933703. PubMed ID: 36189269
[TBL] [Abstract][Full Text] [Related]
14. Identification of Pyroptosis-Relevant Signature in Tumor Immune Microenvironment and Prognosis in Skin Cutaneous Melanoma Using Network Analysis.
Zhu Y; Han D; Duan H; Rao Q; Qian Y; Chen Q; Du X; Ni H; Wang S
Stem Cells Int; 2023; 2023():3827999. PubMed ID: 36818162
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer.
Liu Z; Ding M; Qiu P; Pan K; Guo Q
Front Immunol; 2023; 14():1200282. PubMed ID: 37520534
[TBL] [Abstract][Full Text] [Related]
16. Molecular Characterization and Establishment of a Prognostic Model Based on Primary Immunodeficiency Features in Association with RNA Modifications in Triple-Negative Breast Cancer.
Xia H; Xu X; Guo Y; Deng X; Wang Y; Fu S
Genes (Basel); 2023 Dec; 14(12):. PubMed ID: 38136994
[TBL] [Abstract][Full Text] [Related]
17. The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs.
Pan W; Song K; Zhang Y; Yang C; Zhang Y; Ji F; Zhang J; Shi J; Wang K
Front Immunol; 2022; 13():982486. PubMed ID: 36119101
[TBL] [Abstract][Full Text] [Related]
18. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.
Zhou Y; Che Y; Fu Z; Zhang H; Wu H
Front Public Health; 2022; 10():902378. PubMed ID: 35875026
[TBL] [Abstract][Full Text] [Related]
19. An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer.
Li XF; Fu WF; Zhang J; Song CG
BMC Cancer; 2022 Jun; 22(1):619. PubMed ID: 35668369
[TBL] [Abstract][Full Text] [Related]
20. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.
Yan C; Niu Y; Li F; Zhao W; Ma L
J Transl Med; 2022 Oct; 20(1):455. PubMed ID: 36199146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
